<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9825479</article-id>
    <article-id pub-id-type="pmid">36318242</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkac955</article-id>
    <article-id pub-id-type="publisher-id">gkac955</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ASCancer Atlas: a comprehensive knowledgebase of alternative splicing in human cancers</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0923-639X</contrib-id>
        <name>
          <surname>Wu</surname>
          <given-names>Song</given-names>
        </name>
        <aff><institution>National Genomics Data Center &amp; CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing 100101</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing 100049</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Huang</surname>
          <given-names>Yue</given-names>
        </name>
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing 100101</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing 100049</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9136-451X</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Mochen</given-names>
        </name>
        <aff><institution>National Genomics Data Center &amp; CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing 100101</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing 100049</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gong</surname>
          <given-names>Zheng</given-names>
        </name>
        <aff><institution>National Genomics Data Center &amp; CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing 100101</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing 100049</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Guoliang</given-names>
        </name>
        <aff><institution>National Genomics Data Center &amp; CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing 100101</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing 100049</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5739-861X</contrib-id>
        <name>
          <surname>Zheng</surname>
          <given-names>Xinchang</given-names>
        </name>
        <aff><institution>National Genomics Data Center &amp; CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing 100101</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1834-9684</contrib-id>
        <name>
          <surname>Zong</surname>
          <given-names>Wenting</given-names>
        </name>
        <aff><institution>National Genomics Data Center &amp; CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing 100101</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing 100049</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhao</surname>
          <given-names>Wei</given-names>
        </name>
        <aff><institution>National Genomics Data Center &amp; CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing 100101</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing 100049</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Xing</surname>
          <given-names>Peiqi</given-names>
        </name>
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing 100101</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Li</surname>
          <given-names>Rujiao</given-names>
        </name>
        <!--lirj@big.ac.cn-->
        <aff><institution>National Genomics Data Center &amp; CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing 100101</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing 100049</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR3" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Liu</surname>
          <given-names>Zhaoqi</given-names>
        </name>
        <!--liuzq@big.ac.cn-->
        <aff><institution>CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing 100101</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing 100049</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9922-9723</contrib-id>
        <name>
          <surname>Bao</surname>
          <given-names>Yiming</given-names>
        </name>
        <!--baoym@big.ac.cn-->
        <aff><institution>National Genomics Data Center &amp; CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation</institution>, <addr-line>Beijing 100101</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>University of Chinese Academy of Sciences</institution>, <addr-line>Beijing 100049</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +86 10 84097858; Fax: +86 10 84097720; Email: <email>baoym@big.ac.cn</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Zhaoqi Liu. Tel: +86 10 84097398; Email: <email>liuzq@big.ac.cn</email></corresp>
      <corresp id="COR3">Correspondence may also be addressed to Rujiao Li. Tel: +86 10 84097638; Email: <email>lirj@big.ac.cn</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>06</day>
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-11-01">
      <day>01</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>01</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <volume>51</volume>
    <issue>D1</issue>
    <fpage>D1196</fpage>
    <lpage>D1204</lpage>
    <history>
      <date date-type="accepted">
        <day>13</day>
        <month>10</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>29</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="received">
        <day>15</day>
        <month>8</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkac955.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Alternative splicing (AS) is a fundamental process that governs almost all aspects of cellular functions, and dysregulation in this process has been implicated in tumor initiation, progression and treatment resistance. With accumulating studies of carcinogenic mis-splicing in cancers, there is an urgent demand to integrate cancer-associated splicing changes to better understand their internal cross-talks and functional consequences from a global view. However, a resource of key functional AS events in human cancers is still lacking. To fill the gap, we developed ASCancer Atlas (<ext-link xlink:href="https://ngdc.cncb.ac.cn/ascancer" ext-link-type="uri">https://ngdc.cncb.ac.cn/ascancer</ext-link>), a comprehensive knowledgebase of aberrant splicing in human cancers. Compared to extant databases, ASCancer Atlas features a high-confidence collection of 2006 cancer-associated splicing events experimentally proved to promote tumorigenesis, a systematic splicing regulatory network, and a suit of multi-scale online analysis tools. For each event, we manually curated the functional axis including upstream splicing regulators, splicing event annotations, downstream oncogenic effects, and possible therapeutic strategies. ASCancer Atlas also houses about 2 million computationally putative splicing events. Additionally, a user-friendly web interface was built to enable users to easily browse, search, visualize, analyze, and download all splicing events. Overall, ASCancer Atlas provides a unique resource to study the functional roles of splicing dysregulation in human cancers.</p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Key Research and Development Program of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100012166</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2021YFF0703704</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Strategic Priority Research Program of the Chinese Academy of Sciences</institution>
          </institution-wrap>
        </funding-source>
        <award-id>XDB38030200</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>32170565</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Genomics Data Center Construction of Chinese Academy of Sciences</institution>
          </institution-wrap>
        </funding-source>
        <award-id>WX145XQ07-04</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Professional Association of the Alliance of International Science Organizations</institution>
          </institution-wrap>
        </funding-source>
        <award-id>ANSO-PA-2020-07</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Open Biodiversity and Health Big Data Programme of IUBS</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Key Technology Talent Program of the Chinese Academy of Sciences</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>CAS Hundred Talents Program</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="9"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>Pre-mRNA splicing is a fundamental process in mammalian gene expression, with nearly 95% of human genes undergoing alternative splicing (AS) to generate protein diversity (<xref rid="B1" ref-type="bibr">1</xref>). Over the past decade, there have been extensive evidences showing that aberrations in mRNA splicing contribute to neoplastic transformation, tumor progression and therapeutic resistance (<xref rid="B2" ref-type="bibr">2</xref>). Splicing dysregulation can alter a multitude of critical cellular processes, covering all cancer hallmarks (<xref rid="B3" ref-type="bibr">3</xref>). For instance, AS of <italic toggle="yes">PKM</italic> regulates tumor metabolism (<xref rid="B4" ref-type="bibr">4</xref>), the splicing variants of <italic toggle="yes">CD44</italic> contribute to epithelial to mesenchymal transition (<xref rid="B5" ref-type="bibr">5</xref>), pre-mRNA splicing of <italic toggle="yes">BCL2L1</italic> or <italic toggle="yes">MCL1</italic> induces apoptosis (<xref rid="B6" ref-type="bibr">6</xref>), the splicing variant <italic toggle="yes">RAC1b</italic> is associated with cell growth (<xref rid="B7" ref-type="bibr">7</xref>). The recent large-scale genomic analysis has revealed the mutational landscape of splicing-related genes in human cancers, which provides genetic evidence directly linking RNA splicing dysregulation to cancers (<xref rid="B8" ref-type="bibr">8</xref>). Moreover, a comprehensive pan-cancer study showed that tumors harbor up to 30% more splicing events and potential neo-junctions versus normal tissues (<xref rid="B9" ref-type="bibr">9</xref>). These analyses highlight the pervasive existence of pathogenic splicing changes in human cancers.</p>
    <p>To date, several useful cancer splicing resources have been established with different purposes. For example, OncoSplicing (<ext-link xlink:href="http://www.oncosplicing.com/" ext-link-type="uri">http://www.oncosplicing.com/</ext-link>) aims to provide clinically relevant alternative splicing events (<xref rid="B10" ref-type="bibr">10</xref>). LncAS2Cancer (<ext-link xlink:href="https://lncrna2as.cd120.com/" ext-link-type="uri">https://lncrna2as.cd120.com/</ext-link>) mainly focuses on alternative splicing of lncRNAs (<xref rid="B11" ref-type="bibr">11</xref>). ExonSkipDB is a functional annotation database only about exon skipping events (<xref rid="B12" ref-type="bibr">12</xref>). CancerSplicingQTL is designed to identify potential splicing quantitative trait loci (<xref rid="B13" ref-type="bibr">13</xref>). All these databases were built based on AS events identified from computational tools by analyzing cancer transcriptome datasets. Although computationally extensive, only a small subset of these events has been successfully validated experimentally. In addition, simply a tiny subset of the validated events is crucial for tumorigenesis. It remains a great challenge to extract AS events functionally relevant to cancers from the lengthy list of computational predictions. Meanwhile, the archival of cancer-associated AS events from the tremendous efforts of mechanism studies is of great necessity to systematically understand the regulation of altered splicing events and their associations in cancers. Unfortunately, there is still a lack of such resources, which serve as not only a collection of computationally putative AS events for correlation-based analysis, but more importantly, a knowledgebase of key functional AS events together with its upstream splicing regulators, downstream oncogenic effects and possible therapeutic strategies.</p>
    <p>To fill this gap, we present ASCancer Atlas, a comprehensive knowledgebase of alternative splicing in human cancers for browsing, searching, visualizing, analyzing and downloading cancer-associated splicing events (CASE), as well as computationally putative splicing events (CPSE). In the current release, a total of 2006 high-confidence CASE were manually curated from 610 publications. These CASE have a unified curation model, including upstream splicing regulations, splicing event annotations, downstream oncogenic effects, and possible treatments. Meanwhile, ASCancer Atlas houses about 2 million CPSE, covering 33 TCGA (<xref rid="B14" ref-type="bibr">14</xref>) cancer types and 31 GTEx (<xref rid="B15" ref-type="bibr">15</xref>) normal tissues. In addition, an interactive splicing visualization tool and a multi-dimensional online analysis toolkit were equipped to further explore the splicing events. Collectively, ASCancer Atlas provides the first knowledgebase of carcinogenic AS in human cancers, which can help users to investigate the full spectrum of splicing dysregulation in cancers and will become a value-added resource when more and more splicing variants are identified as targets for cancer treatment. The overall design of ASCancer Atlas is shown in Figure <xref rid="F1" ref-type="fig">1</xref>.</p>
    <fig position="float" id="F1">
      <label>Figure 1.</label>
      <caption>
        <p>Schematic overview of ASCancer Atlas. It mainly includes two categories of splicing events: CASE and CPSE. In addition, a user-friendly web interface is provided where users can browse, search, visualize, analyze and download all splicing events of interest. Abbreviations: AS: alternative splicing. PTC: premature termination codon. ES: exon skipping. IR: Intron retention. A3SS: alternative 3′ splice site. A5SS: alternative 5′ splice site. MEX: mutually exclusive exons.</p>
      </caption>
      <graphic xlink:href="gkac955fig1" position="float"/>
    </fig>
  </sec>
  <sec id="SEC2">
    <title>DATA COLLECTION AND PROCESSING</title>
    <sec id="SEC2-1">
      <title>Cancer-associated splicing events curation</title>
      <p>To provide high-confidence cancer-associated splicing events, ASCancer Atlas set up a standardized and stringent curation process, mainly involving literature searching and filtering, as well as information retrieval and annotations. Firstly, we screened about 2000 literatures in PubMed (<xref rid="B16" ref-type="bibr">16</xref>) using the search term (‘alternative splicing’ OR ‘splicing variant’) AND (‘cancer’ OR ‘tumor’), and picked out the cancer-associated splicing events validated by experimental methods, such as RT-PCR and Western blot. Secondly, we manually curated the complete functional axis of mis-splicing events, including upstream splicing regulations, aberrant splicing events, downstream oncogenic effects, and potential therapeutic interventions. Lastly, the key information of each study was also recorded, such as genomic coordinates, transcript IDs, ORF annotations, cancer types/cell lines, experimental primers, and publication details.</p>
    </sec>
    <sec id="SEC2-2">
      <title>Computationally putative splicing events mining</title>
      <p>The computationally putative splicing events were mined from the pan-cancer atlas project of alternative splicing analysis of 8705 tumor patients across 33 cancer types and 31 normal tissues (<ext-link xlink:href="https://gdc.cancer.gov/about-data/publications/PanCanAtlas-Splicing-2018" ext-link-type="uri">https://gdc.cancer.gov/about-data/publications/PanCanAtlas-Splicing-2018</ext-link>) (<xref rid="B9" ref-type="bibr">9</xref>). ASCancer Atlas used a series of filtering criteria referred to other useful cancer splicing resources (<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>), including three main steps: (i) keep the AS events, which have available PSI values for more than one-third of the cohort; (ii) keep the AS events with median PSI value &gt;0.1; (iii) keep the AS events with at least 10 reads supporting the event.</p>
      <p>In order to further identify the cancer-specific splicing events, differential AS analysis was performed between disease and normal samples. As most TCGA cancer types lack enough matched normal controls, we took an alternative way to compare the splicing differences between TCGA tumors and GTEx samples of the corresponding tissue types. Differential AS analysis was performed for TCGA cancer types with at least 30 tumor samples and 10 adjacent normal samples or at least 10 normal samples in the corresponding GTEx tissue types. The Wilcox rank sum test was used to evaluate the significance of the difference. The splicing events with |delta PSI| ≥ 0.1 and BH adjusted <italic toggle="yes">P</italic>-value ≤ 0.05 were selected as cancer-specific events.</p>
    </sec>
    <sec id="SEC2-3">
      <title>Splicing events visualization and splicing analysis toolkit</title>
      <p>More than a repository of cancer-related splicing events, ASCancer Atlas also developed a series of visualization and online analysis functions to further investigate the splicing events. To visualize the splicing events, human genome annotation GENCODE v19 (<xref rid="B17" ref-type="bibr">17</xref>) was adopted, including sequence information, local splicing switches, transcript structures, isoform composition, and Pfam (<xref rid="B18" ref-type="bibr">18</xref>) domain annotations. In addition, a suit of online splicing analysis tools was developed. We built a <italic toggle="yes">Splicing Regulatory Network</italic> by integrating the splicing regulators and corresponding targets, which were all manually curated from the published literatures. <italic toggle="yes">Splicing Regulatory Explorer</italic> was built to interactively explore the potential splicing regulatory mechanism based on TCGA multi-omics evidence. The splicing datasets were processed as previously mentioned, and the matched genetic mutations (SNPs and CNVs) and downstream expression datasets were downloaded and preprocessed from UCSC Xena (<xref rid="B19" ref-type="bibr">19</xref>). For each splicing event, Fisher's exact test and Pearson correlation analysis were performed to identify potential genetic lesions and expression factors that may explain the splicing event, respectively. The phenotype datasets that support <italic toggle="yes">Survival Analysis</italic> and <italic toggle="yes">Cancer Staging Analysis</italic> of splicing events were collected from the TCGA pan-cancer (PANCAN) project. Survival analysis and cancer staging analysis were performed by R package survival v3.3.1 (<ext-link xlink:href="https://cran.r-project.org/web/packages/survival/index.html" ext-link-type="uri">https://cran.r-project.org/web/packages/survival/index.html</ext-link>), survminer v0.4.9 (<ext-link xlink:href="https://github.com/kassambara/survminer" ext-link-type="uri">https://github.com/kassambara/survminer</ext-link>) and ggpubr v0.4.0 (<ext-link xlink:href="https://mirrors.pku.edu.cn/cran/web/packages/ggpubr/index.html" ext-link-type="uri">https://mirrors.pku.edu.cn/cran/web/packages/ggpubr/index.html</ext-link>). By integrating drug-gene interactions data from multiple sources, e.g. the Drug–Gene Interaction Database (DGIdb) (<xref rid="B20" ref-type="bibr">20</xref>), DrugBank (<xref rid="B21" ref-type="bibr">21</xref>), RCSB PDB (<xref rid="B22" ref-type="bibr">22</xref>) and BioLiP (<xref rid="B23" ref-type="bibr">23</xref>), the ligand-receptor interactions of each drug–gene interaction were obtained. To clarify the impact of different isoforms of the same gene on drug response, the relevant sequences including the binding pocket sequence, target sequence, isoform sequences, and Pfam domain sequences were extracted, and multiple sequence alignment (MSA) was performed by using Clustal Omega provided in the R package msa v1.28.0 (<xref rid="B24" ref-type="bibr">24</xref>). The result of MSA was plotted by R package ggmsa v1.2.3 (<xref rid="B25" ref-type="bibr">25</xref>). Moreover, the PDBe Molstar (<ext-link xlink:href="https://github.com/molstar/pdbe-molstar.git" ext-link-type="uri">https://github.com/molstar/pdbe-molstar.git</ext-link>) plugin was embedded to interactively view the 3D structure of ligand-receptor interactions. The isoform-specific protein-protein interactions (PPIs) network supporting <italic toggle="yes">Splicing Interaction Analysis</italic> was constructed as described in CanIsoNet (<xref rid="B26" ref-type="bibr">26</xref>).</p>
    </sec>
    <sec id="SEC2-4">
      <title>Database framework and web implementation</title>
      <p>ASCancer Atlas was built with Node.js (<ext-link xlink:href="https://nodejs.org/en/" ext-link-type="uri">https://nodejs.org/en/</ext-link>) and deployed in the Centos Linux environment. The back-end database was stored in MongoDB (<ext-link xlink:href="https://www.mongodb.com/" ext-link-type="uri">https://www.mongodb.com/</ext-link>), a free and popular document-based data model. The front-end web user interfaces were developed using Vue.js (<ext-link xlink:href="https://vuejs.org/" ext-link-type="uri">https://vuejs.org/</ext-link>). For data visualization, Highcharts (<ext-link xlink:href="https://www.highcharts.com/" ext-link-type="uri">https://www.highcharts.com/</ext-link>) and D3.js (<ext-link xlink:href="https://d3js.org/" ext-link-type="uri">https://d3js.org/</ext-link>) were used to provide interactive charts. Furthermore, the basic data analysis and processing were implemented using R 4.1 (<ext-link xlink:href="https://www.r-project.org/" ext-link-type="uri">https://www.r-project.org/</ext-link>).</p>
    </sec>
  </sec>
  <sec id="SEC3">
    <title>DATABASE CONTENTS AND USAGE</title>
    <sec id="SEC3-1">
      <title>Splicing events summary and statistics</title>
      <p>ASCancer Atlas aims to provide the most comprehensive cancer-related splicing resources for global researchers. The current version contains two categories of splicing events: CASE and CPSE. ASCancer Atlas houses about 2 million CPSE to characterize the splicing landscapes in human cancers, covering 1 111 805 splicing events of 33 TCGA cancer types and 867 164 splicing events of 31 GTEx normal tissues. Moreover, it also contains 46 591 cancer-specific splicing events. All CPSE are publicly accessible at <ext-link xlink:href="https://ngdc.cncb.ac.cn/ascancer/download" ext-link-type="uri">https://ngdc.cncb.ac.cn/ascancer/download</ext-link> and can be freely downloaded for further analysis.</p>
      <p>More importantly and distinctively, ASCancer Atlas built the first repository of experimentally validated CASE with established oncogenic roles summarized from extensive functional studies. By manually curating 610 published literatures, a total of 2006 high-confidence CASE with detailed information were archived, involving 29 cancer primary sites and 60 human cancer subtypes. For each CASE, ASCancer Atlas records the complete information of upstream splicing regulators, splicing event annotations, main downstream oncogenic effects and potential treatment targets. This layered structure may help users to rapidly capture the functional axis of aberrant splicing of their interest, quickly design experimental validations in their own research cases, and compare their unique findings in the context of previous research discoveries.</p>
    </sec>
    <sec id="SEC3-2">
      <title>User-friendly web interfaces for browsing, retrieving and visualizing splicing events</title>
      <p>As shown in Figure <xref rid="F2" ref-type="fig">2</xref>, ASCancer Atlas designed a series of user-friendly web interfaces that enable users to easily browse, retrieve and visualize splicing events. The ‘Home’ page provides a comprehensive overview, where users can freely navigate by the quick search function which provided inquiries of splicing regulator, gene name, cancer type or splicing effect (Figure <xref rid="F2" ref-type="fig">2A</xref>). Users can also directly browse and inquire the CASE or CPSE according to the advanced search function provided by the ‘Browse’ page. In addition, this page provides additional hyperlinks to <italic toggle="yes">Gene Summary</italic>, <italic toggle="yes">Splicing Details</italic>, <italic toggle="yes">Splicing Visualization</italic>, and <italic toggle="yes">Splicing Toolkit</italic> pages (Figure <xref rid="F2" ref-type="fig">2B</xref>). <italic toggle="yes">Gene Summary</italic> page shows the detailed information of gene, including <italic toggle="yes">Basic Information, Gene Expression and Isoform Percentage in Pan-Cancer, Transcript Information and Structure, Alternative Splicing Models, CASE</italic> and <italic toggle="yes">CPSE. Splicing Details</italic> page provides the detailed curation information of each CASE, including <italic toggle="yes">Splicing Event Description</italic>, <italic toggle="yes">Sample &amp; Method Information</italic>, <italic toggle="yes">Literature Information</italic>, <italic toggle="yes">PSI distribution in Pan-Cancer</italic>, <italic toggle="yes">Canonical Transcript</italic> and <italic toggle="yes">Splicing Variant</italic> (Figure <xref rid="F2" ref-type="fig">2C</xref>). <italic toggle="yes">Splicing Visualization</italic> page provides interactive visualization of all collected CASE and CPSE of a single gene, and shows the PSI distribution of each event in TCGA pan-cancer. Users can also directly view the splicing changes at the local genomic region, the whole transcript and protein levels (Figure <xref rid="F2" ref-type="fig">2D</xref>).</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Thumbnails of web interfaces in ASCancer Atlas. (<bold>A</bold>) Quick search function provided in the ‘Home’ page. (<bold>B</bold>) CASE or CPSE list, as well as visualization and analysis hyperlinks provided in ‘Browse’ page. (<bold>C</bold>) ‘Gene Summary’ and ‘Splicing Details’ pages show the full-scale metadata of each gene and splicing event. (<bold>D</bold>) Interactively visualize splicing events at the local genomic region, the whole transcript and protein levels. (<bold>E</bold>) A suit of online splicing analysis tools equipped in ASCancer Atlas, including <italic toggle="yes">Splicing Regulatory Network</italic>, <italic toggle="yes">Splicing Regulatory Explorer</italic>, <italic toggle="yes">Survival Analysis</italic>, <italic toggle="yes">Cancer Staging Analysis</italic>, <italic toggle="yes">Splicing-derived Drug Response</italic> and <italic toggle="yes">Isoform-specific PPIs Network</italic>. Abbreviations: AS: alternative splicing. UTR: untranslated region. MDS: myelodysplastic syndromes. AML: acute myeloid leukemia. BRCA: breast invasive carcinoma. PSI: percent spliced in.</p>
        </caption>
        <graphic xlink:href="gkac955fig2" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-3">
      <title>Interactive splicing analysis toolkit</title>
      <p>ASCancer Atlas has an online splicing analysis toolkit to further explore the cancer splicing in multiple aspects, involving potential regulators discovery (<italic toggle="yes">Splicing Regulatory Network</italic> and <italic toggle="yes">Splicing Regulatory Explorer</italic>), clinical relevance (<italic toggle="yes">Survival Analysis</italic> and <italic toggle="yes">Cancer Staging Analysis</italic>) and treatment suggestion (<italic toggle="yes">Splicing-derived Drug Response</italic> and <italic toggle="yes">Isoform-specific PPIs Network</italic>) (Figure <xref rid="F2" ref-type="fig">2E</xref>).</p>
      <sec id="SEC3-3-1">
        <title>Splicing regulatory network</title>
        <p>A recent study suggested that splicing dysregulation tends to exert physiological functions in the form of coordinated splicing networks, not a single event (<xref rid="B27" ref-type="bibr">27</xref>). Splicing disorders in cancers are further complicated by the multi-maps between splicing targets and <italic toggle="yes">trans-</italic>acting splicing factors, as well as internal regulations between the splicing factors. ASCancer Atlas provides so far the most complete mis-splicing regulatory network in human cancers, which attempts to link all cancer-associated splicing events from individual studies together in a global view for a better understanding of the coordinated effects of splicing dysregulation (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>). Users can interactively view their interested splicing regulators or the corresponding target genes from a systematic and global perspective.</p>
      </sec>
      <sec id="SEC3-3-2">
        <title>Splicing regulatory explorer</title>
        <p>Alterations in <italic toggle="yes">trans</italic>-acting splicing regulatory factors accounts for most splicing dysregulation in human cancers, especially in hematological malignancies (<xref rid="B28" ref-type="bibr">28</xref>). ASCancer Atlas developed an online tool to uncover the potential splicing regulators based on TCGA multi-omics evidence. At present, the tool supports the exploration of potential splicing regulators from the levels of genetic variants (SNVs/CNVs) and transcriptional expressions. Briefly, with selected event and cancer type, the tool provides an interactive mutation oncoprint and expression heatmap with samples (columns) sorted by the splicing intensity, together with statistics from the pre-ranked enrichment test. For each AS event, the top 10 potential regulators are presented by default and users can also manually check customized genes. In addition, the tool can also help users to view the correlation between gene expression and PSI of AS events. This tool was designed to reveal the full spectrum and possible synergistic combinations of splicing regulatory mechanisms. Likewise, this function would help users to target potential regulatory candidates and design experiments to test any causal associations.</p>
      </sec>
      <sec id="SEC3-3-3">
        <title>Survival analysis and cancer staging analysis</title>
        <p>Survival analysis allows users, especially clinicians, to rapidly estimate the prognostic significance of a given splicing event in the specified cancer type. This may assist them to focus on the candidate splicing events for constructing the prognosis prediction model, and ultimately for cancer treatment. It was reported that AS plays a critical role in developmental processes and is temporally regulated precisely (<xref rid="B29" ref-type="bibr">29</xref>). Therefore, the cancer staging analysis tool was developed in ASCancer Atlas to help users to view the sequential dynamics of a given splicing event at different pathological stages of tumors.</p>
      </sec>
      <sec id="SEC3-3-4">
        <title>Splicing-derived drug response</title>
        <p>AS in cancers may cause therapeutic resistance by changing the binding affinity of targeting agents (<xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref>). This tool allows users to explore the impact of AS on drug-target interactions at the isoform level. Users can investigate the perturbation of different isoforms of the same gene on the drug binding interface by entering the name of gene or drug of interest. In addition, users can also interactively manipulate the 3D structure of receptor-ligand interactions and view the result of multiple sequence alignment for each receptor–ligand interaction to explore how AS affects drug-gene interactions and leads to drug resistance. This tool would help to develop new therapeutic strategies to overcome the splicing-derived drug resistance.</p>
      </sec>
      <sec id="SEC3-3-5">
        <title>Isoform-specific PPIs network</title>
        <p>Splicing dysregulation in cancers may lead to the emergence of cancer-specific isoform switches, and thereby affecting PPIs. This tool aims to explore the functional roles of alternative splicing on PPIs at the isoform level. Users can clearly view the missing or retained isoform-specific PPIs network by entering gene or transcript ID of interest. Users can also set the maximum number of PPIs for visualization.</p>
      </sec>
    </sec>
    <sec id="SEC3-4">
      <title>Demonstrations of ASCancer atlas usage</title>
      <p>ASCancer Atlas has a wide range of application scenarios, and one key task in cancer-associated splicing studies is to find the correct regulator of functional mis-splicing events in cancers. Here, we demonstrate how to achieve this by ASCancer Atlas. We first test on a number of CASE with known regulators as positive controls. Decades of efforts have indicated that frequently altered splicing factors are key drivers of malignant tumors, especially in hematological malignancies (<xref rid="B8" ref-type="bibr">8</xref>). As show in Figure <xref rid="F3" ref-type="fig">3A</xref>, studies indicated that <italic toggle="yes">SRSF2-</italic>P95H mutation leads to aberrant splicing of <italic toggle="yes">EZH2</italic> and <italic toggle="yes">INTS3</italic> in acute myeloid leukemia (AML). These aberrant splicing introduce a premature termination codon (PTC) expected to cause nonsense-mediated decay and degradation of mis-spliced mRNA, which leads to impaired hematopoietic differentiation (<xref rid="B32" ref-type="bibr">32</xref>,<xref rid="B33" ref-type="bibr">33</xref>). Moreover, Liu <italic toggle="yes">et al.</italic> found that <italic toggle="yes">SF3B1-</italic>K700E mutation induces cryptic 3’ splice site usage in one protein phosphatase 2A subunit <italic toggle="yes">PPP2R5A</italic>, which results in <italic toggle="yes">MYC</italic> and <italic toggle="yes">BCL2</italic> activations (<xref rid="B34" ref-type="bibr">34</xref>). Angela <italic toggle="yes">et al.</italic> also revealed that abnormal splicing of <italic toggle="yes">CTNNB1</italic> is caused by <italic toggle="yes">U2AF1-</italic>S34F mutation (<xref rid="B35" ref-type="bibr">35</xref>). In addition, not only mutations in splicing factors, but also altered expression level may cause carcinogenic mis-splicing. For example, down-regulation of splicing regulator <italic toggle="yes">MBNL1</italic> increases exon 2 skipping of <italic toggle="yes">MAP2K7</italic>, which increases cancer stemness and drives tumor dedifferentiation (<xref rid="B36" ref-type="bibr">36</xref>). All these well-studied dysregulation of CASE above can be perfectly reproduced by our online analysis feature: <italic toggle="yes">Splicing Regulatory Explorer</italic> from the toolkit module of ASCancer Atlas (Figure <xref rid="F3" ref-type="fig">3B</xref>, <xref rid="F3" ref-type="fig">C</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S2</xref>).</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Demonstrations of ASCancer Atlas usage by case studies. (<bold>A</bold>) Examples of known splicing dysregulation in human cancers including carcinogenic mis-splicing events, their regulatory mechanism and oncogenic effects. (<bold>B</bold>) Correlation between <italic toggle="yes">MBNL1</italic> expression and PSI values of <italic toggle="yes">MAP2K7</italic> AS in the TCGA-BRCA cohort. Analysis done by the online tool <italic toggle="yes">Splicing Regulatory Explorer</italic> of ASCancer Atlas. (<bold>C</bold>) <italic toggle="yes">SRSF2</italic> mutation oncoprint with columns sorted by the splicing intensity of <italic toggle="yes">INTS3</italic> AS in TCGA-LAML (left). <italic toggle="yes">SF3B1</italic> mutation oncoprint with columns sorted by the splicing intensity of <italic toggle="yes">BRD9</italic> AS in TCGA-UVM (right). <italic toggle="yes">P</italic>-values were calculated from pre-ranked enrichment test. Analysis done by the online tool <italic toggle="yes">Splicing Regulatory Explorer</italic> of ASCancer Atlas. (<bold>D</bold>) Identification of <italic toggle="yes">LSM14A</italic> cassette exon 5 skipping event in the TCGA-LAML cohort and validation of putative <italic toggle="yes">SRSF1</italic> regulator by knockdown experiments in human K562 leukemia cell lines. Correlation between <italic toggle="yes">SRSF1</italic> expression and event PSI in the TCGA-LAML cohort, analysis done by <italic toggle="yes">Splicing Regulatory Explorer</italic> (left), exon 5 inclusion preference after knocking down <italic toggle="yes">SRSF1</italic> in K562 (middle), and splicing changes between <italic toggle="yes">SRSF1</italic> knockdowns and counterparts in K562, <italic toggle="yes">P</italic>-value was calculated from t-test (right). (<bold>E</bold>) Identification of <italic toggle="yes">MAGOH</italic> cassette exon 3 skipping event in the TCGA-LAML cohort and validation of putative <italic toggle="yes">U2AF2</italic> regulator by knockdown experiments in human K562 leukemia cell lines. Correlation between <italic toggle="yes">U2AF2</italic> expression and event PSI in the TCGA-LAML cohort, analysis done by <italic toggle="yes">Splicing Regulatory Explorer</italic> (left), exon 3 inclusion preference after knocking down <italic toggle="yes">U2AF2</italic> in K562 (middle), and splicing changes between <italic toggle="yes">U2AF2</italic> knockdowns and counterparts in K562, <italic toggle="yes">P</italic>-value was calculated from t-test (right). Abbreviations: NES: normalized enrichment score. AS: alternative splicing. PTC: premature termination codon. NMD: nonsense-mediated decay. BRCA: breast invasive carcinoma. LAML: acute myeloid leukemia. UVM: uveal melanoma. PSI: percent spliced in.</p>
        </caption>
        <graphic xlink:href="gkac955fig3" position="float"/>
      </fig>
      <p>Next, in addition to successfully capture known splicing dysregulation of CASE, ASCancer Atlas is also capable of predicting unknown regulatory factors of CPSE. Following the above knowledge that splicing aberrations could result from expression changes of splicing factors, we identified AS events, whose PSI value is significantly correlated with the expression of splicing factors by <italic toggle="yes">Splicing Regulatory Explorer</italic> function. Specifically, in the TCGA-LAML cohort, we found that exon 5 skipping of <italic toggle="yes">LSM14A</italic> is positively correlated with <italic toggle="yes">SRSF1</italic> expression, while enhanced <italic toggle="yes">U2AF2</italic> expression is associated with exon 3 skipping of <italic toggle="yes">MAGOH</italic>. To verify these findings, we downloaded the RNA-Seq data from the knockdown experiments using human K562 cells from the ENCODE (<xref rid="B37" ref-type="bibr">37</xref>) database. Strikingly, the splicing changes from these knockdown experiments are highly consistent with our findings by ASCancer Atlas. The exon 5 inclusion level of <italic toggle="yes">LSM14A</italic> is significantly reduced when knocking down <italic toggle="yes">SRSF1</italic> (Figure <xref rid="F3" ref-type="fig">3D</xref>), the exon 3 of <italic toggle="yes">MAGOH</italic> is more skipped after knocking down <italic toggle="yes">U2AF2</italic> (Figure <xref rid="F3" ref-type="fig">3E</xref>), which indicates that <italic toggle="yes">SRSF1</italic> and <italic toggle="yes">U2AF2</italic> could be the real regulators of these splicing events, respectively. More such evidences can be found in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S2</xref>.</p>
    </sec>
  </sec>
  <sec id="SEC4">
    <title>CONCLUDING REMARKS AND FUTURE DEVELOPMENT</title>
    <p>Ever-increasing evidences have suggested that pre-mRNA mis-splicing can fuel the initiation, progression or drug resistance of cancers. To the best of our knowledge, ASCancer Atlas is the first knowledgebase of carcinogenic AS in human cancers, which provides a comprehensive resource including CASE, CPSE, interactive splicing visualization and multi-scale online splicing analysis toolkit. Different from the existing data-oriented splicing databases, ASCancer Atlas has unique strengths as the following: (i) it collects a total of 2006 high-confidence CASE, and each CASE features a standardized curation model. The regulatory mechanisms and determined oncogenic splicing effects have been verified through functional experiments, which can assist researchers to rapidly capture the functional axis for experimental testing; (ii) by connecting all CASE and their regulators from hundreds of publications, it provides the most complete and systematic mis-splicing regulatory networks in human cancers, enabling a better understanding of the coordinated effects of splicing disorders; (iii) equipped with a suit of online splicing analysis tools, which facilitate the exploration of splicing events in multiple dimensions and contribute to the identification of potential regulators, clinically relevant events, and possible therapeutic targets; (iv) the concept of website design follows a concise logic axis of standard study on cancer splicing from splicing regulator, mis-splicing events, oncogenic effects to therapeutic interventions. The emphasis of this layered web organization aims to better serve and meet the requirements of the different components of a conventional study on aberrant splicing in cancers.</p>
    <p>As one of the many resources of the National Genomics Data Center (<xref rid="B38" ref-type="bibr">38</xref>), ASCancer Atlas will be devoted to serving as an open-access and comprehensive one-stop platform for AS studies. Future directions include regular curation of newly reported CASE every three months, continuous expansion of CPSE every six months, and exploratory development of handy online splicing tools. For any new-added CPSE, ASCancer Atlas will strictly follow the same computational pipeline as the pan-cancer atlas splicing project and perform quality control strategies to reduce the possible batch effect. Additionally, given that tumors contain more neo-junctions than normal samples, we intend to provide a new analysis tool of ‘putative splicing-derived neoantigens’ for cancer immunotherapy by predicting the major histocompatibility complex binding ability of tumor-specific splicing isoforms. With the ever-increase amount of long-read RNA sequencing data of normal and malignant tissues, we will consider building an independent module in the next release to store the splicing resources identified from the third-generation sequencing data. Due to the important regulation roles of epigenetic factors in alternative splicing, we will add DNA methylation factors to <italic toggle="yes">Splicing Regulatory Explorer</italic> tool by establishing connections with related databases, such as MethBank (<xref rid="B39" ref-type="bibr">39</xref>) and EWAS Open Platform (<xref rid="B40" ref-type="bibr">40</xref>). In all, we believe that ASCancer Atlas will attract considerable interest in a wide range of audiences including cancer biologists, molecular biologists, computational biologists and clinical oncologists.</p>
  </sec>
  <sec sec-type="data-availability" id="SEC5">
    <title>DATA AVAILABILITY</title>
    <p>ASCancer Atlas is freely available online at <ext-link xlink:href="https://ngdc.cncb.ac.cn/ascancer" ext-link-type="uri">https://ngdc.cncb.ac.cn/ascancer</ext-link>. Users can directly download the splicing resources without registration or login.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkac955_Supplemental_File</label>
      <media xlink:href="gkac955_supplemental_file.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>ACKNOWLEDGEMENTS</title>
    <p>We thank Lili Hao, Yingke Ma, Lizhi Yi, Hongen Kang, Yaokai Jia and Tao Zhang for helpful suggestions. We also appreciate a number of users and two anonymous reviewers for reporting bugs and providing constructive feedback.</p>
  </ack>
  <sec id="SEC6">
    <title>SUPPLEMENTARY DATA</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkac955#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC7">
    <title>FUNDING</title>
    <p>National Key Research &amp; Development Program of China [2021YFF0703704]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB38030200]; National Natural Science Foundation of China [32170565]; Genomics Data Center Construction of Chinese Academy of Sciences [WX145XQ07-04]; Professional Association of the Alliance of International Science Organizations [ANSO-PA-2020-07]; Open Biodiversity and Health Big Data Programme of IUBS; Key Technology Talent Program of the Chinese Academy of Sciences; CAS Hundred Talents Program. Funding for open access charge: National Key Research &amp; Development Program of China [2021YFF0703704].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Rabadan</surname><given-names>R.</given-names></string-name></person-group><article-title>Computing the role of alternative splicing in cancer</article-title>. <source>Trends Cancer</source>. <year>2021</year>; <volume>7</volume>:<fpage>347</fpage>–<lpage>358</lpage>.<pub-id pub-id-type="pmid">33500226</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stanley</surname><given-names>R.F.</given-names></string-name>, <string-name><surname>Abdel-Wahab</surname><given-names>O.</given-names></string-name></person-group><article-title>Dysregulation and therapeutic targeting of RNA splicing in cancer</article-title>. <source>Nat. Cancer</source>. <year>2022</year>; <volume>3</volume>:<fpage>536</fpage>–<lpage>546</lpage>.<pub-id pub-id-type="pmid">35624337</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bonnal</surname><given-names>S.C.</given-names></string-name>, <string-name><surname>Lopez-Oreja</surname><given-names>I.</given-names></string-name>, <string-name><surname>Valcarcel</surname><given-names>J.</given-names></string-name></person-group><article-title>Roles and mechanisms of alternative splicing in cancer - implications for care</article-title>. <source>Nat. Rev. Clin. Oncol.</source><year>2020</year>; <volume>17</volume>:<fpage>457</fpage>–<lpage>474</lpage>.<pub-id pub-id-type="pmid">32303702</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Kim</surname><given-names>J.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>B.</given-names></string-name>, <string-name><surname>Ying</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ji</surname><given-names>K.Y.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>W.</given-names></string-name>, <string-name><surname>Mai</surname><given-names>T.</given-names></string-name>, <string-name><surname>Dou</surname><given-names>W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>MTR4 drives liver tumorigenesis by promoting cancer metabolic switch through alternative splicing</article-title>. <source>Nat. Commun.</source><year>2020</year>; <volume>11</volume>:<fpage>708</fpage>.<pub-id pub-id-type="pmid">32024842</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>F.L.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>J.L.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>H.Y.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>R.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>L.F.</given-names></string-name>, <string-name><surname>Shao</surname><given-names>Z.M.</given-names></string-name>, <string-name><surname>Li</surname><given-names>D.Q.</given-names></string-name></person-group><article-title>Cancer-Associated MORC2-Mutant M276I regulates an hnRNPM-Mediated CD44 splicing switch to promote invasion and metastasis in triple-negative breast cancer</article-title>. <source>Cancer Res.</source><year>2018</year>; <volume>78</volume>:<fpage>5780</fpage>–<lpage>5792</lpage>.<pub-id pub-id-type="pmid">30093560</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ge</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Schuster</surname><given-names>M.B.</given-names></string-name>, <string-name><surname>Pundhir</surname><given-names>S.</given-names></string-name>, <string-name><surname>Rapin</surname><given-names>N.</given-names></string-name>, <string-name><surname>Bagger</surname><given-names>F.O.</given-names></string-name>, <string-name><surname>Sidiropoulos</surname><given-names>N.</given-names></string-name>, <string-name><surname>Hashem</surname><given-names>N.</given-names></string-name>, <string-name><surname>Porse</surname><given-names>B.T.</given-names></string-name></person-group><article-title>The splicing factor RBM25 controls MYC activity in acute myeloid leukemia</article-title>. <source>Nat. Commun.</source><year>2019</year>; <volume>10</volume>:<fpage>172</fpage>.<pub-id pub-id-type="pmid">30635567</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xing</surname><given-names>S.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>W.</given-names></string-name>, <string-name><surname>He</surname><given-names>X.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wei</surname><given-names>H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>S.T.</given-names></string-name>, <string-name><surname>Shu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>L.</given-names></string-name>, <string-name><surname>Zhong</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DIS3L2 promotes progression of hepatocellular carcinoma via hnRNP U-Mediated alternative splicing</article-title>. <source>Cancer Res.</source><year>2019</year>; <volume>79</volume>:<fpage>4923</fpage>–<lpage>4936</lpage>.<pub-id pub-id-type="pmid">31331910</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab><string-name><surname>Seiler</surname><given-names>M.</given-names></string-name>, <string-name><surname>Peng</surname><given-names>S.</given-names></string-name>, <string-name><surname>Agrawal</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Palacino</surname><given-names>J.</given-names></string-name>, <string-name><surname>Teng</surname><given-names>T.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>P.</given-names></string-name>, <string-name><surname>Smith</surname><given-names>P.G.</given-names></string-name>, <string-name><surname>Buonamici</surname><given-names>S.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>L.</given-names></string-name></person-group><article-title>Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types</article-title>. <source>Cell Rep.</source><year>2018</year>; <volume>23</volume>:<fpage>282</fpage>–<lpage>296</lpage>.<pub-id pub-id-type="pmid">29617667</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kahles</surname><given-names>A.</given-names></string-name>, <string-name><surname>Lehmann</surname><given-names>K.V.</given-names></string-name>, <string-name><surname>Toussaint</surname><given-names>N.C.</given-names></string-name>, <string-name><surname>Huser</surname><given-names>M.</given-names></string-name>, <string-name><surname>Stark</surname><given-names>S.G.</given-names></string-name>, <string-name><surname>Sachsenberg</surname><given-names>T.</given-names></string-name>, <string-name><surname>Stegle</surname><given-names>O.</given-names></string-name>, <string-name><surname>Kohlbacher</surname><given-names>O.</given-names></string-name>, <string-name><surname>Sander</surname><given-names>C.</given-names></string-name>, <string-name><surname>Ratsch</surname><given-names>G.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Comprehensive analysis of alternative splicing across tumors from 8,705 patients</article-title>. <source>Cancer Cell</source>. <year>2018</year>; <volume>34</volume>:<fpage>211</fpage>–<lpage>224</lpage>.<pub-id pub-id-type="pmid">30078747</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Yao</surname><given-names>X.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>H.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Tian</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yan</surname><given-names>L.</given-names></string-name>, <string-name><surname>Duan</surname><given-names>C.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.</given-names></string-name><etal>et al</etal>.</person-group><article-title>OncoSplicing: an updated database for clinically relevant alternative splicing in 33 human cancers</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>50</volume>:<fpage>D1340</fpage>–<lpage>D1347</lpage>.</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Deng</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>H.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L.</given-names></string-name></person-group><article-title>LncAS2Cancer: a comprehensive database for alternative splicing of lncRNAs across human cancers</article-title>. <source>Brief. Bioinform</source>. <year>2021</year>; <volume>22</volume>:<fpage>bbaa179</fpage>.<pub-id pub-id-type="pmid">32820322</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>P.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Yiya</surname><given-names>K.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>X.</given-names></string-name></person-group><article-title>ExonSkipDB: functional annotation of exon skipping event in human</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D896</fpage>–<lpage>D907</lpage>.<pub-id pub-id-type="pmid">31642488</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tian</surname><given-names>J.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Mei</surname><given-names>S.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>N.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ke</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Gong</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zou</surname><given-names>D.</given-names></string-name>, <string-name><surname>Peng</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>CancerSplicingQTL: a database for genome-wide identification of splicing QTLs in human cancer</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>; <volume>47</volume>:<fpage>D909</fpage>–<lpage>D916</lpage>.<pub-id pub-id-type="pmid">30329095</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hutter</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zenklusen</surname><given-names>J.C.</given-names></string-name></person-group><article-title>The cancer genome atlas: creating lasting value beyond its data</article-title>. <source>Cell</source>. <year>2018</year>; <volume>173</volume>:<fpage>283</fpage>–<lpage>285</lpage>.<pub-id pub-id-type="pmid">29625045</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carithers</surname><given-names>L.J.</given-names></string-name>, <string-name><surname>Moore</surname><given-names>H.M.</given-names></string-name></person-group><article-title>The genotype-tissue expression (GTEx) project</article-title>. <source>Biopreserv. Biobank</source>. <year>2015</year>; <volume>13</volume>:<fpage>307</fpage>–<lpage>308</lpage>.<pub-id pub-id-type="pmid">26484569</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sayers</surname><given-names>E.</given-names></string-name>, <string-name><surname>Bolton</surname><given-names>E.</given-names></string-name>, <string-name><surname>Brister</surname><given-names>J.</given-names></string-name>, <string-name><surname>Canese</surname><given-names>K.</given-names></string-name>, <string-name><surname>Chan</surname><given-names>J.</given-names></string-name>, <string-name><surname>Comeau</surname><given-names>D.</given-names></string-name>, <string-name><surname>Connor</surname><given-names>R.</given-names></string-name>, <string-name><surname>Funk</surname><given-names>K.</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>C.</given-names></string-name>, <string-name><surname>Kim</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Database resources of the national center for biotechnology information</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D10</fpage>–<lpage>D17</lpage>.<pub-id pub-id-type="pmid">33095870</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frankish</surname><given-names>A.</given-names></string-name>, <string-name><surname>Diekhans</surname><given-names>M.</given-names></string-name>, <string-name><surname>Jungreis</surname><given-names>I.</given-names></string-name>, <string-name><surname>Lagarde</surname><given-names>J.</given-names></string-name>, <string-name><surname>Loveland</surname><given-names>J.E.</given-names></string-name>, <string-name><surname>Mudge</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Sisu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Wright</surname><given-names>J.C.</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>J.</given-names></string-name>, <string-name><surname>Barnes</surname><given-names>I.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Gencode 2021</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D916</fpage>–<lpage>D923</lpage>.<pub-id pub-id-type="pmid">33270111</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mistry</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chuguransky</surname><given-names>S.</given-names></string-name>, <string-name><surname>Williams</surname><given-names>L.</given-names></string-name>, <string-name><surname>Qureshi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Salazar</surname><given-names>G.A.</given-names></string-name>, <string-name><surname>Sonnhammer</surname><given-names>E.L.L.</given-names></string-name>, <string-name><surname>Tosatto</surname><given-names>S.C.E.</given-names></string-name>, <string-name><surname>Paladin</surname><given-names>L.</given-names></string-name>, <string-name><surname>Raj</surname><given-names>S.</given-names></string-name>, <string-name><surname>Richardson</surname><given-names>L.J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Pfam: the protein families database in 2021</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D412</fpage>–<lpage>D419</lpage>.<pub-id pub-id-type="pmid">33125078</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goldman</surname><given-names>M.</given-names></string-name>, <string-name><surname>Craft</surname><given-names>B.</given-names></string-name>, <string-name><surname>Hastie</surname><given-names>M.</given-names></string-name>, <string-name><surname>Repečka</surname><given-names>K.</given-names></string-name>, <string-name><surname>McDade</surname><given-names>F.</given-names></string-name>, <string-name><surname>Kamath</surname><given-names>A.</given-names></string-name>, <string-name><surname>Banerjee</surname><given-names>A.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Rogers</surname><given-names>D.</given-names></string-name>, <string-name><surname>Brooks</surname><given-names>A.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Visualizing and interpreting cancer genomics data via the xena platform</article-title>. <source>Nat. Biotechnol.</source><year>2020</year>; <volume>38</volume>:<fpage>675</fpage>–<lpage>678</lpage>.<pub-id pub-id-type="pmid">32444850</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Freshour</surname><given-names>S.</given-names></string-name>, <string-name><surname>Kiwala</surname><given-names>S.</given-names></string-name>, <string-name><surname>Cotto</surname><given-names>K.</given-names></string-name>, <string-name><surname>Coffman</surname><given-names>A.</given-names></string-name>, <string-name><surname>McMichael</surname><given-names>J.</given-names></string-name>, <string-name><surname>Song</surname><given-names>J.</given-names></string-name>, <string-name><surname>Griffith</surname><given-names>M.</given-names></string-name>, <string-name><surname>Griffith</surname><given-names>O.</given-names></string-name>, <string-name><surname>Wagner</surname><given-names>A.</given-names></string-name></person-group><article-title>Integration of the drug-gene interaction database (DGIdb 4.0) with open crowdsource efforts</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D1144</fpage>–<lpage>D1151</lpage>.<pub-id pub-id-type="pmid">33237278</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>D.</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>E.</given-names></string-name>, <string-name><surname>Marcu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Grant</surname><given-names>J.</given-names></string-name>, <string-name><surname>Sajed</surname><given-names>T.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sayeeda</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DrugBank 5.0: a major update to the drugbank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burley</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bhikadiya</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bi</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bittrich</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>L.</given-names></string-name>, <string-name><surname>Crichlow</surname><given-names>G.</given-names></string-name>, <string-name><surname>Christie</surname><given-names>C.</given-names></string-name>, <string-name><surname>Dalenberg</surname><given-names>K.</given-names></string-name>, <string-name><surname>Di Costanzo</surname><given-names>L.</given-names></string-name>, <string-name><surname>Duarte</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>RCSB protein data bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D437</fpage>–<lpage>D451</lpage>.<pub-id pub-id-type="pmid">33211854</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Roy</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name></person-group><article-title>BioLiP: a semi-manually curated database for biologically relevant ligand-protein interactions</article-title>. <source>Nucleic Acids Res.</source><year>2013</year>; <volume>41</volume>:<fpage>D1096</fpage>–<lpage>D1103</lpage>.<pub-id pub-id-type="pmid">23087378</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bodenhofer</surname><given-names>U.</given-names></string-name>, <string-name><surname>Bonatesta</surname><given-names>E.</given-names></string-name>, <string-name><surname>Horejš-Kainrath</surname><given-names>C.</given-names></string-name>, <string-name><surname>Hochreiter</surname><given-names>S.</given-names></string-name></person-group><article-title>msa: an r package for multiple sequence alignment</article-title>. <source>Bioinformatics</source>. <year>2015</year>; <volume>31</volume>:<fpage>3997</fpage>–<lpage>3999</lpage>.<pub-id pub-id-type="pmid">26315911</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname><given-names>L.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>T.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>S.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>F.</given-names></string-name>, <string-name><surname>Lam</surname><given-names>T.T.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>T.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhan</surname><given-names>L.</given-names></string-name>, <string-name><surname>Li</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>ggmsa: a visual exploration tool for multiple sequence alignment and associated data</article-title>. <source>Brief Bioinform</source>. <year>2022</year>; <volume>23</volume>:<fpage>bbac222</fpage>.<pub-id pub-id-type="pmid">35671504</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kahraman</surname><given-names>A.</given-names></string-name>, <string-name><surname>Karakulak</surname><given-names>T.</given-names></string-name>, <string-name><surname>Szklarczyk</surname><given-names>D.</given-names></string-name>, <string-name><surname>von Mering</surname><given-names>C.</given-names></string-name></person-group><article-title>Pathogenic impact of transcript isoform switching in 1,209 cancer samples covering 27 cancer types using an isoform-specific interaction network</article-title>. <source>Sci. Rep.</source><year>2020</year>; <volume>10</volume>:<fpage>14453</fpage>.<pub-id pub-id-type="pmid">32879328</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname><given-names>J.</given-names></string-name>, <string-name><surname>An</surname><given-names>O.</given-names></string-name>, <string-name><surname>Ren</surname><given-names>X.</given-names></string-name>, <string-name><surname>Song</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ke</surname><given-names>X.</given-names></string-name>, <string-name><surname>Ng</surname><given-names>V.H.E.</given-names></string-name>, <string-name><surname>Tay</surname><given-names>D.J.T.</given-names></string-name>, <string-name><surname>Tan</surname><given-names>H.Q.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Multilayered control of splicing regulatory networks by DAP3 leads to widespread alternative splicing changes in cancer</article-title>. <source>Nat. Commun.</source><year>2022</year>; <volume>13</volume>:<fpage>1793</fpage>.<pub-id pub-id-type="pmid">35379802</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Urbanski</surname><given-names>L.M.</given-names></string-name>, <string-name><surname>Leclair</surname><given-names>N.</given-names></string-name>, <string-name><surname>Anczukow</surname><given-names>O.</given-names></string-name></person-group><article-title>Alternative-splicing defects in cancer: splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics</article-title>. <source>Wiley Interdiscip. Rev RNA</source>. <year>2018</year>; <volume>9</volume>:<fpage>e1476</fpage>.<pub-id pub-id-type="pmid">29693319</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weyn-Vanhentenryck</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ustianenko</surname><given-names>D.</given-names></string-name>, <string-name><surname>Duffie</surname><given-names>R.</given-names></string-name>, <string-name><surname>Yan</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Jacko</surname><given-names>M.</given-names></string-name>, <string-name><surname>Martinez</surname><given-names>J.C.</given-names></string-name>, <string-name><surname>Goodwin</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Hengst</surname><given-names>U.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Precise temporal regulation of alternative splicing during neural development</article-title>. <source>Nat. Commun.</source><year>2018</year>; <volume>9</volume>:<fpage>2189</fpage>.<pub-id pub-id-type="pmid">29875359</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Poulikakos</surname><given-names>P.I.</given-names></string-name>, <string-name><surname>Persaud</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Janakiraman</surname><given-names>M.</given-names></string-name>, <string-name><surname>Kong</surname><given-names>X.</given-names></string-name>, <string-name><surname>Ng</surname><given-names>C.</given-names></string-name>, <string-name><surname>Moriceau</surname><given-names>G.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>H.</given-names></string-name>, <string-name><surname>Atefi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Titz</surname><given-names>B.</given-names></string-name>, <string-name><surname>Gabay</surname><given-names>M.T.</given-names></string-name><etal>et al</etal>.</person-group><article-title>RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)</article-title>. <source>Nature</source>. <year>2011</year>; <volume>480</volume>:<fpage>387</fpage>–<lpage>390</lpage>.<pub-id pub-id-type="pmid">22113612</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Antonarakis</surname><given-names>E.S.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Luber</surname><given-names>B.</given-names></string-name>, <string-name><surname>Nakazawa</surname><given-names>M.</given-names></string-name>, <string-name><surname>Roeser</surname><given-names>J.C.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Mohammad</surname><given-names>T.A.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Fedor</surname><given-names>H.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer</article-title>. <source>N. Engl. J. Med.</source><year>2014</year>; <volume>371</volume>:<fpage>1028</fpage>–<lpage>1038</lpage>.<pub-id pub-id-type="pmid">25184630</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>E.</given-names></string-name>, <string-name><surname>Ilagan</surname><given-names>J.O.</given-names></string-name>, <string-name><surname>Liang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Daubner</surname><given-names>G.M.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>S.C.</given-names></string-name>, <string-name><surname>Ramakrishnan</surname><given-names>A.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chung</surname><given-names>Y.R.</given-names></string-name>, <string-name><surname>Micol</surname><given-names>J.B.</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>M.E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition</article-title>. <source>Cancer Cell</source>. <year>2015</year>; <volume>27</volume>:<fpage>617</fpage>–<lpage>630</lpage>.<pub-id pub-id-type="pmid">25965569</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yoshimi</surname><given-names>A.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>K.T.</given-names></string-name>, <string-name><surname>Wiseman</surname><given-names>D.H.</given-names></string-name>, <string-name><surname>Rahman</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Pastore</surname><given-names>A.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>B.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>S.C.</given-names></string-name>, <string-name><surname>Micol</surname><given-names>J.B.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.J.</given-names></string-name>, <string-name><surname>de Botton</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis</article-title>. <source>Nature</source>. <year>2019</year>; <volume>574</volume>:<fpage>273</fpage>–<lpage>277</lpage>.<pub-id pub-id-type="pmid">31578525</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Yoshimi</surname><given-names>A.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Cho</surname><given-names>H.</given-names></string-name>, <string-name><surname>Chun-Wei Lee</surname><given-names>S.</given-names></string-name>, <string-name><surname>Ki</surname><given-names>M.</given-names></string-name>, <string-name><surname>Bitner</surname><given-names>L.</given-names></string-name>, <string-name><surname>Chu</surname><given-names>T.</given-names></string-name>, <string-name><surname>Shah</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Mutations in the RNA splicing factor SF3B1 promote tumorigenesis through MYC stabilization</article-title>. <source>Cancer Discov.</source><year>2020</year>; <volume>10</volume>:<fpage>806</fpage>–<lpage>821</lpage>.<pub-id pub-id-type="pmid">32188705</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brooks</surname><given-names>A.N.</given-names></string-name>, <string-name><surname>Choi</surname><given-names>P.S.</given-names></string-name>, <string-name><surname>de Waal</surname><given-names>L.</given-names></string-name>, <string-name><surname>Sharifnia</surname><given-names>T.</given-names></string-name>, <string-name><surname>Imielinski</surname><given-names>M.</given-names></string-name>, <string-name><surname>Saksena</surname><given-names>G.</given-names></string-name>, <string-name><surname>Pedamallu</surname><given-names>C.S.</given-names></string-name>, <string-name><surname>Sivachenko</surname><given-names>A.</given-names></string-name>, <string-name><surname>Rosenberg</surname><given-names>M.</given-names></string-name>, <string-name><surname>Chmielecki</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events</article-title>. <source>PLoS One</source>. <year>2014</year>; <volume>9</volume>:<fpage>e87361</fpage>.<pub-id pub-id-type="pmid">24498085</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ray</surname><given-names>D.</given-names></string-name>, <string-name><surname>Yun</surname><given-names>Y.C.</given-names></string-name>, <string-name><surname>Idris</surname><given-names>M.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>S.</given-names></string-name>, <string-name><surname>Boot</surname><given-names>A.</given-names></string-name>, <string-name><surname>Iain</surname><given-names>T.B.H.</given-names></string-name>, <string-name><surname>Rozen</surname><given-names>S.G.</given-names></string-name>, <string-name><surname>Tan</surname><given-names>P.</given-names></string-name>, <string-name><surname>Epstein</surname><given-names>D.M.</given-names></string-name></person-group><article-title>A tumor-associated splice-isoform of MAP2K7 drives dedifferentiation in MBNL1-low cancers via JNK activation</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2020</year>; <volume>117</volume>:<fpage>16391</fpage>–<lpage>16400</lpage>.<pub-id pub-id-type="pmid">32601196</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hitz</surname><given-names>B.C.</given-names></string-name>, <string-name><surname>Gabdank</surname><given-names>I.</given-names></string-name>, <string-name><surname>Hilton</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Kagda</surname><given-names>M.S.</given-names></string-name>, <string-name><surname>Lam</surname><given-names>B.</given-names></string-name>, <string-name><surname>Myers</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Sud</surname><given-names>P.</given-names></string-name>, <string-name><surname>Jou</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>K.</given-names></string-name><etal>et al</etal>.</person-group><article-title>New developments on the encyclopedia of DNA elements (ENCODE) data portal</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D882</fpage>–<lpage>D889</lpage>.<pub-id pub-id-type="pmid">31713622</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><collab>CNCB-NGDC Members and Partners</collab><article-title>Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2023</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <pub-id pub-id-type="doi">10.1093/nar/gkac1073</pub-id>.</mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zong</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zou</surname><given-names>D.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>W.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>X.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Y.</given-names></string-name><etal>et al</etal>.</person-group><article-title>MethBank 4.0: an updated database of DNA methylation across a variety of species</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <pub-id pub-id-type="doi">10.1093/nar/gkac969</pub-id>.</mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiong</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Li</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>W.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>X.</given-names></string-name>, <string-name><surname>Zou</surname><given-names>D.</given-names></string-name>, <string-name><surname>Zong</surname><given-names>W.</given-names></string-name><etal>et al</etal>.</person-group><article-title>EWAS open platform: integrated data, knowledge and toolkit for epigenome-wide association study</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>50</volume>:<fpage>D1004</fpage>–<lpage>D1009</lpage>.</mixed-citation>
    </ref>
  </ref-list>
</back>
